Provider review
Ro Body tirzepatide review
What Ro Body charges, what is included, who prescribes, which pharmacy fills it, where it operates — and how much of that we confirmed ourselves rather than took from the website.
This is an independent assessment of Ro Body's tirzepatide program against our published 100-point rubric. It separates what the provider states from what we verified. No pricing, scoring or state data has been captured yet, so nothing below is presented as a finding. Verification status appears beside every field.
What is distinctive about this programme
The annual plan changes the structure, not just the price
Ro's annual prepayment is reported to cut $50 a month from oral medication and $150 a month from injectable medication, and to halve the membership from $149 to $74. That is a larger structural change than most competitors' prepaid discounts, which typically move only the medication line.
On the monthly plan, Zepbound at $399 medication plus $149 membership is $548 all-in — against $449 direct from LillyDirect with no membership. The annual plan closes most of that gap.
Dose escalation applies
Medication prices run $199 to $399 by dose for injectables and $199 to $299 for orals, so the all-in figure moves with titration. The first month is discounted — $299 medication for Zepbound, $149 for oral — and those are introductory rates excluded from our rankings.
What to weigh
Ro is a large, established platform with substantial clinical infrastructure. The pricing question is whether the service layer justifies $1,788 a year on the monthly plan, or $888 on the annual, when both manufacturers sell direct. For patients who want the platform, the annual plan is materially the better structure; for patients who want the medication at the lowest price, LillyDirect and NovoCare are cheaper.
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| Semaglutide brand injectable, FDA-approved | $348 | Reported |
Where it holds up
- Annual plan reduces both medication cost and membership, halving the latter to $74
- Large established platform with substantial clinical infrastructure
- Wide brand range including both manufacturers' products
Where it does not
- $149 monthly membership on the standard plan, $1,788 a year
- Zepbound at $548 all-in monthly against $449 direct from LillyDirect
- Medication prices escalate by dose
- First-month rates are introductory
- Figures are third-party reported and not yet captured by us
| Field | Position |
|---|---|
| Membership | Separate and required |
| Dose structure | Escalates with dose or not established |
| Lowest captured figure | $348/mo, month-to-month |
| Evidence status | Third-party reported, pending our own capture |
| Pharmacy named to us | No — provider-reported only |
Show this figure as a table
| Item | Points | Evidence |
|---|---|---|
| Pricing transparency and all-in value | 25 pts | Verified |
| Clinical oversight and care continuity | 20 pts | Verified |
| Pharmacy traceability and quality disclosures | 15 pts | Verified |
| Regulatory clarity and consumer disclosures | 15 pts | Verified |
| State access and operational reliability | 10 pts | Verified |
| Cancellation, billing and support transparency | 10 pts | Verified |
| Evidence quality and data availability | 5 pts | Verified |
Pricing, all-in
Plan total and monthly equivalent are calculated by us from the provider's published figures, using the same formula applied to every provider on this site. A price is only a price once the required fees are inside it.
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| Ro | month_to_month | brand injectable, FDA-approved | — | $348 | — | $348 | Recurring | Reported | 2026-07-06 |
How this sits against the market
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| Found | $169 | Reported |
| NexLife (opens nexlife.us in a new tab) | $186 | Verified |
| NexLife (opens nexlife.us in a new tab) | $190 | Verified |
| NexLife | $195 | Verified |
| NexLife | $215 | Verified |
| Shed | $245 | Reported |
| Mochi Health | $278 | Reported |
| Enhance.MD | $280 | Reported |
| Eden | $298 | Reported |
| Noom Med | $299 | Reported |
| TrimRx | $349 | Reported |
| MEDVi | $399 | Pending |
| bmiMD | $399 | Reported |
Show this figure as a table
| Component | Amount |
|---|---|
| Medication | not captured |
| Membership | not captured |
| Shipping | not captured |
| Dose surcharge | not captured |
| Consultation | not captured |
| Labs | not captured |
| All-in total | not captured |
| Cost component | Inside the advertised figure? | Charged anyway? |
|---|---|---|
| Medication | yes | yes |
| Membership or program fee | no | — |
| Shipping | no | — |
| Higher-dose surcharge | no | — |
| Initial consultation | no | — |
| Required laboratory work | no | — |
| Cancellation or restocking terms | no | — |
A dash means no figure held. How we grade evidence.
This chart stays empty until two or more dated captures exist. Historical values are never estimated or backfilled from a provider's current page.
Show this figure as a table
| Item | This provider | Category median |
|---|---|---|
| All-in monthly | not captured | not captured |
| Membership fee | not captured | not captured |
| Rubric score | not captured | not captured |
What is included, and what is not
Where it holds up
- nothing verified yet
Where it does not
- nothing verified yet
Where it operates
State availability is verified against the provider's own checkout or a support confirmation, state by state, with a capture date. A provider serving forty states is not nationwide, and we do not describe it that way.
Show this figure as a table
| Status | Records | Share |
|---|---|---|
| Researched and verified | 0 | 0% |
| Not yet researched | 51 | 100% |
Clinical model
Pharmacy and fulfilment
Billing, cancellation and support
What changed
Show this figure as a table
| No events recorded. |
- no entriesNothing has changed yet because nothing has been published yet. Entries appear here when a verified figure, score or conclusion changes, never for a typo fix.
How this compares to the category
Once enough providers are scored, this section reports where Ro Body sits against the median for each rubric category, not against a hand-picked competitor.
| Question | Worth | Their answer | Status |
|---|---|---|---|
| Pharmacy traceability and quality disclosures | 15 pts | — | Not answered Pending |
| Clinical oversight and care continuity | 20 pts | — | Not answered Pending |
| State access and operational reliability | 10 pts | — | Not answered Pending |
| Cancellation, billing and support transparency | 10 pts | — | Not answered Pending |
A dash means no figure held. How we grade evidence.
Questions readers actually ask
Is Ro Body the cheapest option?
We will not answer that until the all-in figures are captured for the whole comparison set. A cheapest claim needs a defined comparison group, a stated program type and a capture date, or it is just an adjective.
Is this review sponsored?
No. No provider pays for coverage, placement, a score or a link, and providers do not see a review before it publishes.
Is compounded tirzepatide the same as Zepbound?
No. Compounded preparations are not FDA-approved products and there is no generic tirzepatide. Approval of the brand product does not extend to a compounded preparation.
Related on this site
- All provider reviewsProviders
- NexLife Tirzepatide ReviewProviders
- Hims & Hers Tirzepatide ReviewProviders
- Mochi Health Tirzepatide ReviewProviders
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Mounjaro vs ZepboundPillar / Money
- Zepbound vs MounjaroComparisons
- Tirzepatide Cost in 2026Pillar / Money
Related coverage
- PlushCare Tirzepatide Review
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- A 2026 Study Finds Tirzepatide and B12 Can Chemically Bond — Forming a Molecule Not in the Approved Drug
- EVOKE and EVOKE+: Oral Semaglutide Made No Difference to Alzheimer's Progression
- FDA Sends 25 More Warning Letters Over Compounded GLP-1 Marketing Claims
- FDA Proposes Permanent Exclusion of Semaglutide, Tirzepatide and Liraglutide From the 503B Bulks List
- Comment Period on the GLP-1 Bulks Proposal Extended to 30 July
- FDA Signals It Will Restrict GLP-1 Active Ingredients Used in Non-Approved Compounded Products
Tirzepatide Ranked. “Ro Body Tirzepatide Review.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/providers/ro-body/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 15 of 70 price records in this dataset were read at the source by us: 9 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.